Board of Directors

Dr Edwin Hertzog

Non-executive Chairman

Nationality: South African

Committee memberships: Clinical Performance and Sustainability Committee, Investment Committee (Chair), Nomination Committee (Chair)

Dr Edwin Hertzog was appointed as the non-executive Chairman of the Company on 15 February 2016. Prior to the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Limited in 2016, he served as a director of Mediclinic International Limited from 1983 and as the Chairman from 1992. As a specialist anaesthetist, he was commissioned by the then Rembrandt group (now Remgro) in 1983 to undertake a feasibility study on the establishment of a private hospital group, and three years later, in 1986, Mediclinic International Limited (then Medi-Clinic Corporation Limited) was listed on the JSE. He was appointed as the first managing director of Mediclinic International Limited upon its establishment in 1983. He served as executive Chairman of Mediclinic from 1992 until August 2012 when he retired from his executive role, but remained on the Board as non-executive Chairman. He also serves as the non-executive deputy Chairman of Remgro and is a past Chairman of the council of the Stellenbosch University.

Qualifications: Dr Hertzog holds a Bachelor of Medicine and Bachelor of Surgery (MB, ChB); Fellowship of the Faculty of Anaesthesiologists (SA); and a Doctor of Philosophy (Ph.D) (honoris causa).

Dr Ronnie van der Merwe

Chief Executive Officer

Nationality: South African

Committee membership: Clinical Performance and Sustainability Committee, Investment Committee

Dr Ronnie van der Merwe is a specialist anaesthetist who worked in the medical insurance industry before joining the Group in 1999 as Clinical Manager. He established the Clinical Information, Advanced Analytics, Health Information Management and Clinical Services functions at Mediclinic, and subsequently served as the Mediclinic Group’s Chief Clinical Officer. He was appointed as an executive director of Mediclinic International Limited in 2010 up to the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Limited. He was appointed as the Chief Executive Officer from 1 June 2018. He serves as a non-executive director of Spire Healthcare Group plc from 24 May 2018.

Qualifications: Dr Van der Merwe holds a medical degree from the University of Stellenbosch (MB, Ch.B); a Diploma in Anaesthetics from the College of Anaesthetists of South Africa (DA (SA)); the Fellowship of the College of Anaesthetists of South Africa (FCA (SA)); and completed the Advanced Management Programme at Harvard Business School.

Jurgens Myburgh

Chief Financial Officer

Nationality: South African

Committee membership: Investment Committee

Mr Jurgens Myburgh was appointed as an executive director and Chief Financial Officer of the Company on 1 August 2016. Prior to joining the Mediclinic Group, he served as Chief Financial Officer at Datatec Limited, an international information and communications technology group, which operates in over 60 countries, and before that, worked at The Standard Bank of South Africa Limited as Executive Vice President of Investment Banking.

Qualifications: Mr Myburgh holds an Honours degree in Accounting from the University of Johannesburg (B.Comm. (Hons)); and is a qualified Chartered Accountant with the South African Institute of Chartered Accountants.

Mr Danie Meintjes

Non-Executive Director

Nationality: South African

Committee membership: Investment Committee

Mr Danie Meintjes served as the Chief Executive Officer of the Mediclinic Group from 2010 up to his retirement on 1 June 2018, remaining on the Board as an executive director until 31 July 2018 and currently serves as a non-executive director from 1 August 2018. He was appointed as an executive director and Chief Executive Officer of the Company on 15 February 2016. Prior to the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Limited in 2016, he served as the Chief Executive Officer of Mediclinic International Limited from 2010. He has served in various management positions in the Remgro group, before joining the Mediclinic Group in 1985 as the hospital manager of Mediclinic Sandton. He was appointed as a member of Mediclinic’s Executive Committee in 1995 and as a director in 1996. He was seconded to serve as a senior executive of the Group’s operations in Dubai in 2006, and appointed as the Chief Executive Officer of Mediclinic Middle East in 2007. He served as a non-executive director of Spire Healthcare Group plc from 2015, from which position he retired on 24 May 2018.

Qualifications: Mr Meintjes holds an Honours degree in Industrial Psychology from the University of the Free State; and completed the Advanced Management Programme at Harvard Business School.

Desmond Smith

Senior Independent Director

Nationality: South African

Committee memberships: Audit and Risk Committee (Chair), Nomination Committee

Mr Desmond Smith was appointed as an independent non-executive director of the Company on 15 February 2016. Prior to the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Limited in 2016, he served as an independent non-executive director of Mediclinic International Limited from 2008 and as the lead independent director from 2010. He was the Chief Executive Officer of the Sanlam Group from April 1993 to December 1997 and of the Reinsurance Group of America (South Africa) (“RGA(SA)”) from March 1999 to March 2005. He is currently Chairman of RGA(SA) and retired as Chairman of Sanlam Group in June 2017. During his career, he has served on various boards and was president of both the Actuarial Society of South Africa (1996) and the International Actuarial Association (2012).

Qualifications: Mr Smith holds a Bachelor of Science (B.SC.) degree; is a fellow of the Actuarial Society of South Africa; and completed an International Senior Managers Program at Harvard Business School.

Dr Muhadditha Al Hashimi

Independent non-executive director

Nationality: UAE

Committee membership: Clinical Performance and Sustainability Committee

Dr Muhadditha Al Hashimi was appointed as an independent non-executive director of the Company on 1 November 2017. She is also a member of the board of trustees and the Audit and Compliance Committee of the University of Sharjah, and a member of the board of trustees of the UAE Nursing and Midwifery Council and the UAE Genetics Diseases Association. She is the campus director of Higher Colleges of Technology Sharjah Women's College in the UAE. Prior to her current positions, Dr Al Hashimi held the position of executive Dean of the Faculty of Health Sciences, Higher Colleges of Technology; acting deputy vice-chancellor of Academic Affairs at the Higher Colleges of Technology; Chief Executive Officer of the Mohammed Bin Rashid Al Maktoum Academic Medical Center in Dubai; Deputy Chief Executive Officer of Tatweer LLC; Chief Executive Officer of Dubai Healthcare City (both members of Dubai Holding); and a director of education of the Harvard Medical School Dubai Centre.

Qualifications: Dr Al Hashimi obtained a Doctorate in Public Health from the University of Texas; a Master's degree in Clinical Laboratory Sciences from the University of Minnesota; and a Bachelor's degree in Medical Technology from the University of Minnesota.

Jannie Durand

Non-executive director

Nationality: South African

Committee memberships: Investment Committee, Nomination Committee

Mr Jannie Durand* was appointed as a non-executive director of the Company on 15 February 2016. Prior to the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Limited in 2016, he served as a non-executive director of Mediclinic International Limited from 2012. He joined the Rembrandt group in 1996 and was appointed as the Chief Executive Officer of Remgro Limited in 2012, which holds a 44.56% interest in the Company. In his current role, with more than 20 years’ experience in the investment industry, he acts as a non-executive director of various companies, including Distell Group Limited, FirstRand Limited, RCL Foods Limited and RMI Holdings Limited.

Qualifications: Mr Durand holds an Honours degree in Accountancy from the University of Stellenbosch (B.Acc. (Hons)); a Master’s of Philosophy in Management Studies from Oxford University (M.Phil. (Management Studies)); and is a qualified Chartered Accountant with the South African Institute of Chartered Accountants.

Mr Pieter Uys, the Head of Strategic Investment at Remgro Limited, is appointed as the alternate to Mr Durand since 7 April 2016. Prior to joining Remgro, Mr Uys was a founding member and ultimately became the Chief Executive Officer of the Vodacom group, one of the leading mobile networks in Africa.

Qualifications: Mr Uys holds an M.Eng. (Electrical) degree; and an MBA from the University of Stellenbosch.

Alan Grieve

Independent non-executive director

Nationality: British

Committee memberships: Audit and Risk Committee, Disclosure Committee (Chairman), Investment Committee

Alan Grieve was appointed as an independent non-executive director of the Company on 15 February 2016 following the Combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Limited. Prior to the Combination, he served as an independent non-executive director of Mediclinic International Limited from 2012. He is a non-executive director of Reinet Investments Manager S.A., having served as its Chief Executive Officer from 2012 to 2014 and Chief Financial Officer from 2008 to 2011. He was the Director of Corporate Affairs of Compagnie Financière Richemont SA. Prior to joining Richemont in 1986, he worked with the predecessor firms of PricewaterhouseCoopers and Ernst & Young.

Qualifications: He holds an Honours degree in Business Administration from Heriot-Watt University, Edinburgh (B.A. (Hons)); and is also a member of the Institute of Chartered Accountants of Scotland.

Dr Felicity Harvey

Independent non-executive director

Nationality: British

Committee membership: Clinical Performance and Sustainability Committee (Chair), Nomination Committee

Dr Felicity Harvey was appointed as an independent non-executive director of the Company on 3 October 2017. She serves as a Visiting Professor at the Institute of Global Health Innovation at Imperial College London; is a non-executive director of Guy's and St Thomas' NHS Foundation Trust in London; a Trustee of Royal Trinity Hospice in London; and a member of the WHO Independent Oversight & Advisory Committee for Health Emergencies. Previously, she served as Director-General of Public and International Health at the UK Department of Health; Director of the UK Prime Minister's Delivery Unit, then HM Treasury’s Performance and Reform Unit; Head of the Medicines, Pharmacy and Industry Group at the Department of Health; Director of Prison Health at Her Majesty's Prison Service; Head of Quality Management at NHS Executive and private secretary to the Chief Medical Officer of the Department of Health of the United Kingdom. Dr Harvey was appointed CBE in 2008.

Qualifications: Dr Harvey qualified in medicine in 1980; is an honorary fellow of the Royal College of Physicians; a fellow of the Faculty of Public Health; has an international MBA from Henley Management College; and has gained a Postgraduate Diploma in Clinical Microbiology at The Royal London Hospital College, University of London.

Seamus Keating

Independent non-executive director

Nationality: Irish

Committee memberships: Audit and Risk Committee, Clinical Performance and Sustainability Committee, Remuneration Committee

Mr Seamus Keating was appointed as an independent non-executive director of the Company (then Al Noor Hospitals Group plc) on 5 June 2013 and continues to serve as a director of the Company following the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Limited in 2016. He has over 20 years’ experience in the global technology sector in finance and operational roles, and was a main board director of Logica plc from 2002 until April 2012. He was Chief Financial Officer of Logica plc from 2002 until 2010 when he became Chief Operating Officer and head of its Benelux operations. Prior to his role at Logica plc, he worked for the Olivetti Group in senior finance roles in the UK and Italy. He served as non-executive director and Chairman of the audit committee of Mouchel plc from November 2010 to September 2012. He is currently Chairman of First Derivatives plc, a non-executive director of BGL Group Limited, a non-executive director of Callcredit Information Group plc and a non-executive director of Mi-pay Group plc.

Qualifications: Mr Keating is a fellow of the Chartered Institute of Management Accountants.

Trevor Petersen

Non-Executive Director

Nationality: South African

Committee memberships: Audit and Risk Committee, Remuneration Committee (Chair)

Mr Trevor Petersen was appointed as an independent non-executive director of the Company on 15 February 2016. Prior to the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Limited in 2016, he served as an independent non-executive director of Mediclinic International Limited from 2012. In 1996, he resigned from the University of Cape Town to take up a partnership in the merged firm of PricewaterhouseCoopers Inc. He served as a partner of the national firm from 1997 to 2009 and served as the partner-in-charge of Cape Town and as Chairman of the Western Cape region. He is an independent non-executive director on the board of Media24 (Pty) Ltd (a subsidiary of Naspers Limited) and is currently the managing trustee of the Woodside Village Trust. He has served professional membership associations such as the South African Institute of Chartered Accountants, and was elected the Chairman of the National Body in 2006 and 2007.


Qualifications: Mr Petersen holds an Honours degree in Accountancy from the University of Cape Town (B.Comm. (Hons)); and is a qualified Chartered Accountant with the South African Institute of Chartered Accountants.

Dr Anja Oswald

Non-Executive Director

Nationality: Swiss

Committee memberships: Nomination Committee, Remuneration Committee

Dr Anja Oswald was appointed as an independent non-executive director of the Company on 25 July 2018. She is the CEO of the Klinik Sonnenhalde, a well-established private clinic for psychiatry and psychotherapy with inpatients, day-care clinics and outpatients in Riehen, Switzerland and is Vice-President of the Association of Private Hospitals in Basel. Prior to this, she was Head of Medical and Pharmaceutical Services and Deputy Medical Officer in the Department of Health of the Cantonal Government in Basel and a member of various cantonal, regional and national committees. Dr Oswald was also CEO of a start-up company in the healthcare sector and worked several years as a Medical Doctor in different hospitals.

Qualifications: Dr Oswald holds a Masters in Business Administration from the Rochester-Berne Executive MBA; a Doctorate in Medicine from the University of Basel specialising in orthopaedic surgery and traumatology as well as in sports medicine.  She passed the Board School at the International Centre of Corporate Governance of the University of St. Gallen.